June 24, 2009 08:00 AM Eastern Daylight Time
Neuralstem Enters into Agreement with China Medical University in Taiwan to Develop Stem Cell Stroke Treatment
ROCKVILLE, Md.--(BUSINESS WIRE)--Neuralstem, Inc. (NYSE Amex: CUR) announced today that it has entered into a sponsored research agreement with the China Medical University & Hospital of Taiwan, in Taichung, Taiwan, to prepare for a human clinical trial using Neuralstem’s human spinal cord neural stem cells to treat stroke patients. The therapy will focus on patients whose post-stroke symptoms, including complete or partial paralysis, have stopped improving more than six months after an ischemic stroke. Ischemic stroke, caused by a blockage in a vessel supplying blood to the brain, is the most common type of stroke and affects more than 400,000 people in the United States yearly. There are about 6.5 million stroke survivors in the U.S. alone.
“We are excited to be moving forward in treating stroke with our cells,” said Richard Garr, Neuralstem President & CEO. “The preclinical program, which we expect will take between nine months to a year, will focus on qualifying our existing cGMP (Good Manufacturing Process) spinal cord cells into a human trial program to treat post-stroke symptoms in Taiwan. With a population of nearly 23 million, Taiwan is a substantial and important market in Asia, and China Medical University is the national leader in innovative neurological research and treatments,” added Garr. “We are very pleased to be working with another world-class institution, and with Principal Investigators, Dr. Shinn-Zong Lin, M.D., Ph.D. and Dr. Woei-Cherng Shyu, M.D., Ph.D., as we build out our worldwide network of neurosurgical centers capable of conducting clinical trials, and ultimately delivering our cell therapies.”
http://www.businesswire.com/portal/site ... ewsLang=en
About Neuralstem, Inc.
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem’s IND (Investigational New Drug) application is under review with the FDA for ALS. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. ALS affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year. Pre-clinical work has shown Neuralstem’s cells to extend the life of rats with ALS (as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers), and also reversed paralysis in rats with Ischemic Spastic Paraplegia, (as reported in NEUROSCIENCE; June 29, 2007, in collaboration with researchers at University of California San Diego).
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-Q for the quarter ended March 31, 2009.
For Neuralstem, Inc.
Richard Garr, President, 301-366-4960
Ina McGuinness, Investor Relations, 310-954-1100
Deanne Eagle, Media, 917-837-5866